CN108635621A - Preparation method for the load stem cell fibrin gel for promoting wound healing - Google Patents
Preparation method for the load stem cell fibrin gel for promoting wound healing Download PDFInfo
- Publication number
- CN108635621A CN108635621A CN201810453594.XA CN201810453594A CN108635621A CN 108635621 A CN108635621 A CN 108635621A CN 201810453594 A CN201810453594 A CN 201810453594A CN 108635621 A CN108635621 A CN 108635621A
- Authority
- CN
- China
- Prior art keywords
- concentration
- mixed solution
- solution
- stem cell
- fibrin gel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010073385 Fibrin Proteins 0.000 title claims abstract description 16
- 102000009123 Fibrin Human genes 0.000 title claims abstract description 16
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 title claims abstract description 16
- 229950003499 fibrin Drugs 0.000 title claims abstract description 16
- 210000000130 stem cell Anatomy 0.000 title claims abstract description 16
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- 230000029663 wound healing Effects 0.000 title claims abstract description 10
- 230000001737 promoting effect Effects 0.000 title abstract description 8
- 239000000243 solution Substances 0.000 claims abstract description 19
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims abstract description 12
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims abstract description 12
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims abstract description 12
- 229960003766 thrombin (human) Drugs 0.000 claims abstract description 11
- 108010049003 Fibrinogen Proteins 0.000 claims abstract description 7
- 102000008946 Fibrinogen Human genes 0.000 claims abstract description 7
- 229940012952 fibrinogen Drugs 0.000 claims abstract description 7
- 241000283690 Bos taurus Species 0.000 claims abstract description 6
- 239000002504 physiological saline solution Substances 0.000 claims abstract description 6
- 108090000190 Thrombin Proteins 0.000 claims description 2
- 229960004072 thrombin Drugs 0.000 claims description 2
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 230000003511 endothelial effect Effects 0.000 claims 1
- 229920005573 silicon-containing polymer Polymers 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
- 239000011259 mixed solution Substances 0.000 abstract description 30
- 206010052428 Wound Diseases 0.000 abstract description 11
- 208000027418 Wounds and injury Diseases 0.000 abstract description 11
- 210000002901 mesenchymal stem cell Anatomy 0.000 abstract description 11
- 239000004205 dimethyl polysiloxane Substances 0.000 abstract description 5
- 210000002889 endothelial cell Anatomy 0.000 abstract description 5
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 abstract description 5
- -1 polydimethylsiloxane Polymers 0.000 abstract description 5
- 239000000758 substrate Substances 0.000 abstract description 5
- 230000035876 healing Effects 0.000 abstract description 3
- 238000000034 method Methods 0.000 abstract description 3
- 230000035755 proliferation Effects 0.000 abstract description 2
- 230000009762 endothelial cell differentiation Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000007921 spray Substances 0.000 abstract 1
- 239000000499 gel Substances 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 5
- 239000000017 hydrogel Substances 0.000 description 5
- 230000002439 hemostatic effect Effects 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 208000032544 Cicatrix Diseases 0.000 description 1
- 108010080379 Fibrin Tissue Adhesive Proteins 0.000 description 1
- 101001038021 Lonomia obliqua Lopap Proteins 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/008—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0028—Polypeptides; Proteins; Degradation products thereof
- A61L26/0042—Fibrin; Fibrinogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0028—Polypeptides; Proteins; Degradation products thereof
- A61L26/0047—Specific proteins or polypeptides not covered by groups A61L26/0033 - A61L26/0042
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0057—Ingredients of undetermined constitution or reaction products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/0066—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/04—Materials for stopping bleeding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Materials Engineering (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dispersion Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明公开了一种能促进伤口愈合的载干细胞纤维蛋白凝胶的制备方法，其步骤如下：A、用生理盐水溶解牛纤维蛋白原，配成浓度为5‑30mg/mL的溶液；再加入血管内皮生长因子，得混合液一，混合液一中血管内皮生长因子的浓度为50‑150ng/mL；B、用浓度为0.33‑0.66mol/mL的CaCl2溶液溶解人凝血酶，配成浓度为30‑70iu/mL的人凝血酶溶液；再加入间充质干细胞，得到混合液二，混合液二中间充质干细胞的浓度为60‑80×104个/mL；C、用200μL移液枪将混合液一和混合液二按1:5的体积比，混合滴在聚二甲基硅氧烷基底上；然后，放在37℃的孵箱中，静置4‑12h，即得。该方法制备的载干细胞纤维蛋白凝胶，能诱导干细胞向内皮化分化、促进内皮细胞的增殖、加速皮肤组织的愈合和修复，伤口痊愈快。The invention discloses a preparation method of stem cell-loaded fibrin gel capable of promoting wound healing. The steps are as follows: A. Dissolving bovine fibrinogen with physiological saline to form a solution with a concentration of 5-30 mg/mL; adding Vascular endothelial growth factor, get mixed solution one, the concentration of vascular endothelial growth factor in mixed solution one is 50-150ng/mL; B, be 0.33-0.66mol /mL CaCl solution with concentration Human thrombin is dissolved, is made into concentration Human thrombin solution of 30-70iu/mL; then add mesenchymal stem cells to obtain mixed solution 2, the concentration of mixed solution 2 mesenchymal stem cells is 60-80× 104 /mL; C, pipette with 200 μL Spray mixed solution 1 and mixed solution 2 according to the volume ratio of 1:5, mix and drop on the polydimethylsiloxane substrate; then, put it in an incubator at 37°C and let it stand for 4-12h to obtain. The stem cell-loaded fibrin gel prepared by the method can induce endothelial differentiation of stem cells, promote the proliferation of endothelial cells, accelerate the healing and repair of skin tissues, and quickly heal wounds.
Description
技术领域technical field
本发明涉及一种促伤口愈合的载干细胞纤维蛋白凝胶的制备方法。The invention relates to a preparation method of stem cell-loaded fibrin gel for promoting wound healing.
背景技术Background technique
随着科技的发展，水凝胶在组织细胞培养和药物缓释载体及微胶囊方面的应用越来越多，水凝胶包括天然水凝胶和合成水凝胶。纤维蛋白胶是天然水凝胶中的一种，它能很好地被人体接受，无免疫反应；载有Ca2+的纤维蛋白凝胶则可作为止血材料，对伤口具有良好的止血效果。但其不能补上伤口缺失的细胞，伤口容易形成凹陷的疤痕，痊愈时间长。With the development of science and technology, there are more and more applications of hydrogels in tissue cell culture, drug sustained-release carriers and microcapsules. Hydrogels include natural hydrogels and synthetic hydrogels. Fibrin glue is a kind of natural hydrogel, which can be well accepted by the human body and has no immune reaction; fibrin gel loaded with Ca2+ can be used as a hemostatic material and has a good hemostatic effect on wounds. However, it cannot replace the missing cells in the wound, and the wound is prone to form sunken scars, which take a long time to heal.
发明内容Contents of the invention
本发明的目的是提供一种用于促进伤口愈合的载干细胞纤维蛋白凝胶的制备方法，该方法制备的载干细胞纤维蛋白凝胶，能诱导干细胞向内皮化分化、促进内皮细胞的增殖、加速皮肤组织的愈合和修复，伤口痊愈快。The purpose of the present invention is to provide a preparation method of stem cell-loaded fibrin gel for promoting wound healing. The stem cell-loaded fibrin gel prepared by the method can induce stem cells to differentiate into endothelial cells, promote the proliferation of endothelial cells, accelerate The healing and repair of skin tissue, the wound heals quickly.
本发明实现其发明目的所采用的技术方案是，一种能促进伤口愈合的载干细胞纤维蛋白凝胶的制备方法，其步骤如下：The technical solution adopted by the present invention to realize the purpose of the invention is a preparation method of a stem cell-loaded fibrin gel capable of promoting wound healing, the steps of which are as follows:
A、用生理盐水溶解牛纤维蛋白原，配成浓度为5-30mg/mL的溶液；再加入血管内皮生长因子，得混合液一，混合液一中血管内皮生长因子的浓度为50-150ng/mL；A, dissolve bovine fibrinogen with physiological saline, be made into the solution that concentration is 5-30mg/mL; Add vascular endothelial growth factor again, obtain mixed solution one, the concentration of vascular endothelial growth factor in mixed solution one is 50-150ng/mL mL;
B、用浓度为0.33-0.66mol/mL的CaCl2溶液溶解人凝血酶，配成浓度为30-70iu/mL的人凝血酶溶液；再加入间充质干细胞，得到混合液二，混合液二中间充质干细胞的浓度为60-80×104个/mL；B. Dissolve human thrombin with a CaCl solution with a concentration of 0.33-0.66mol /mL to prepare a human thrombin solution with a concentration of 30-70iu/mL; then add mesenchymal stem cells to obtain mixed solution 2 and mixed solution 2 The concentration of intermediate mesenchymal stem cells is 60-80× 104 cells/mL;
C、用200μL移液枪将混合液一和混合液二按1:5的体积比，混合滴在聚二甲基硅氧烷基底上；然后，放在37℃的孵箱中，静置4-12h，即得。C. Use a 200μL pipette gun to mix the mixed solution 1 and the mixed solution 2 at a volume ratio of 1:5, and drop them on the polydimethylsiloxane substrate; then, put them in an incubator at 37°C and let them stand for 4 -12h, that is.
与现有技术相比，本发明的有益效果是：Compared with prior art, the beneficial effect of the present invention is:
本发明的纤维蛋白凝胶是用凝血酶激活纤维蛋白原形成纤维蛋白，纤维蛋白再交联形成。使用时将其粘合于创口，凝胶中携带的Ca2+能促进人体的凝血酶原激活物的形成，加速伤口的凝血反应，起止血作用；同时，凝胶中包裹的血管内皮生长因子诱导包裹的间充质干细胞向内皮化分化，形成的内皮细胞进入伤口，促进伤口的内皮细胞生长、加速皮肤组织的愈合和修复，伤口痊愈快。The fibrin gel of the present invention is formed by activating fibrinogen with thrombin to form fibrin, and then cross-linking the fibrin. When used, stick it to the wound. The Ca 2+ carried in the gel can promote the formation of prothrombin activator in the human body, accelerate the blood coagulation reaction of the wound, and play a hemostatic effect; at the same time, the vascular endothelial growth factor wrapped in the gel Induce the endothelialization and differentiation of encapsulated mesenchymal stem cells, and the formed endothelial cells enter the wound, promote the growth of endothelial cells in the wound, accelerate the healing and repair of skin tissue, and the wound heals quickly.
进一步，本发明的A、B、C步骤中的操作均在无菌条件下进行。Further, the operations in steps A, B, and C of the present invention are all carried out under sterile conditions.
这样，可以确保制得的凝胶中不含有细菌，避免使用时凝胶中的细菌感染伤口。In this way, it can be ensured that the prepared gel does not contain bacteria, so as to prevent the bacteria in the gel from infecting wounds during use.
下面结合具体实施方式对本发明做进一步的详细说明Below in conjunction with specific embodiment the present invention is described in further detail
具体实施方式Detailed ways
实施例一Embodiment one
一种能促进伤口愈合的载干细胞纤维蛋白凝胶的制备方法，其步骤如下：A preparation method of stem cell-loaded fibrin gel capable of promoting wound healing, the steps are as follows:
A、用生理盐水溶解牛纤维蛋白原，配成浓度为5mg/mL的溶液；再加入血管内皮生长因子，得混合液一，混合液一中血管内皮生长因子的浓度为50ng/mL；A, dissolve bovine fibrinogen with physiological saline, be made into the solution that concentration is 5mg/mL; Add vascular endothelial growth factor again, obtain mixed solution one, the concentration of vascular endothelial growth factor in mixed solution one is 50ng/mL;
B、用浓度为0.33mol/mL的CaCl2溶液溶解人凝血酶，配成浓度为30iu/mL的人凝血酶溶液；再加入间充质干细胞，得到混合液二，混合液二中间充质干细胞的浓度为60×104个/mL；B. Dissolve human thrombin with a CaCl solution with a concentration of 0.33mol /mL to prepare a human thrombin solution with a concentration of 30iu/mL; then add mesenchymal stem cells to obtain mixed solution 2, mixed solution 2 mesenchymal stem cells The concentration is 60×10 4 cells/mL;
C、用200μL移液枪将混合液一和混合液二按1:5的体积比，混合滴在聚二甲基硅氧烷基底上；然后，放在37℃的孵箱中，静置4h，即得。C. Use a 200 μL pipette gun to mix the mixed solution 1 and the mixed solution 2 at a volume ratio of 1:5, and drop them on the polydimethylsiloxane substrate; then, put them in an incubator at 37°C and let them stand for 4 hours , that is.
本例的A、B、C步骤中的操作均在无菌条件下进行。The operations in steps A, B, and C of this example were all carried out under sterile conditions.
实施例二Embodiment two
一种能促进伤口愈合的载干细胞纤维蛋白凝胶的制备方法，其步骤如下：A preparation method of stem cell-loaded fibrin gel capable of promoting wound healing, the steps are as follows:
A、用生理盐水溶解牛纤维蛋白原，配成浓度为10mg/mL的溶液；再加入血管内皮生长因子，得混合液一，混合液一中血管内皮生长因子的浓度为100ng/mL；A, dissolve bovine fibrinogen with physiological saline, be made into the solution that concentration is 10mg/mL; Add vascular endothelial growth factor again, obtain mixed solution one, the concentration of vascular endothelial growth factor in mixed solution one is 100ng/mL;
B、用浓度为0.44mol/mL的CaCl2溶液溶解人凝血酶，配成浓度为50iu/mL的人凝血酶溶液；再加入间充质干细胞，得到混合液二，混合液二中间充质干细胞的浓度为70×104个/mL；B. Dissolve human thrombin with a CaCl solution with a concentration of 0.44mol /mL to prepare a human thrombin solution with a concentration of 50iu/mL; then add mesenchymal stem cells to obtain mixed solution 2, mixed solution 2 mesenchymal stem cells The concentration is 70×10 4 cells/mL;
C、用200μL移液枪将混合液一和混合液二按1:5的体积比，混合滴在聚二甲基硅氧烷基底上；然后，放在37℃的孵箱中，静置8h，即得。C. Use a 200 μL pipette gun to mix the mixed solution 1 and the mixed solution 2 at a volume ratio of 1:5, and drop them on the polydimethylsiloxane substrate; then, put them in an incubator at 37°C and let them stand for 8 hours , that is.
本例的A、B、C步骤中的操作均在无菌条件下进行。The operations in steps A, B, and C of this example were all carried out under sterile conditions.
实施例三Embodiment Three
一种能促进伤口愈合的载干细胞纤维蛋白凝胶的制备方法，其步骤如下：A preparation method of stem cell-loaded fibrin gel capable of promoting wound healing, the steps are as follows:
A、用生理盐水溶解牛纤维蛋白原，配成浓度为30mg/mL的溶液；再加入血管内皮生长因子，得混合液一，混合液一中血管内皮生长因子的浓度为150ng/mL；A, dissolve bovine fibrinogen with physiological saline, be made into the solution that concentration is 30mg/mL; Add vascular endothelial growth factor again, obtain mixed solution one, the concentration of vascular endothelial growth factor in mixed solution one is 150ng/mL;
B、用浓度为0.66mol/mL的CaCl2溶液溶解人凝血酶，配成浓度为70iu/mL的人凝血酶溶液；再加入间充质干细胞，得到混合液二，混合液二中间充质干细胞的浓度为80×104个/mL；B. Dissolve human thrombin with a CaCl solution with a concentration of 0.66mol /mL to prepare a human thrombin solution with a concentration of 70iu/mL; then add mesenchymal stem cells to obtain mixed solution 2, mixed solution 2 mesenchymal stem cells The concentration is 80×10 4 cells/mL;
C、用200μL移液枪将混合液一和混合液二按1:5的体积比，混合滴在聚二甲基硅氧烷基底上；然后，放在37℃的孵箱中，静置12h，即得。C. Use a 200 μL pipette gun to mix the mixed solution 1 and the mixed solution 2 at a volume ratio of 1:5, and drop them on the polydimethylsiloxane substrate; then, put them in an incubator at 37°C and let them stand for 12 hours , that is.
本例的A、B、C步骤中的操作均在无菌条件下进行。The operations in steps A, B, and C of this example were all carried out under sterile conditions.
Claims (2)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810453594.XA CN108635621A (en) | 2018-05-14 | 2018-05-14 | Preparation method for the load stem cell fibrin gel for promoting wound healing |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810453594.XA CN108635621A (en) | 2018-05-14 | 2018-05-14 | Preparation method for the load stem cell fibrin gel for promoting wound healing |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108635621A true CN108635621A (en) | 2018-10-12 |
Family
ID=63755050
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810453594.XA Pending CN108635621A (en) | 2018-05-14 | 2018-05-14 | Preparation method for the load stem cell fibrin gel for promoting wound healing |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108635621A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112263713A (en) * | 2020-09-21 | 2021-01-26 | 苏州大学附属第一医院 | Fibrin hydrogel scaffold loaded with human umbilical cord mesenchymal stem cells and its application |
| CN115463083A (en) * | 2022-08-03 | 2022-12-13 | 湖南师范大学 | Injectable hydrogel material and preparation and application methods thereof |
| CN119454917A (en) * | 2025-01-14 | 2025-02-18 | 温州医科大学 | Preparation method and application of cell lysate gel for treating oral ulcer |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101716382A (en) * | 2009-12-02 | 2010-06-02 | 浙江大学 | Preparation method of trinary composite stent of plasmid DNA / fibrin gel / polymer |
| WO2012103100A1 (en) * | 2011-01-24 | 2012-08-02 | Progenicare, Llc | Compositions and methods for promoting tissue regeneration |
| CN103041453A (en) * | 2013-01-18 | 2013-04-17 | 新乡医学院 | Double-layer skin covering material compositely built by collagen/fibrin glue-VEGF (vascular endothelial growth factor) and mesenchymal stem cell as well as preparation method and application of double-layer skin covering material |
| CN105708860A (en) * | 2016-01-26 | 2016-06-29 | 深圳爱生再生医学科技有限公司 | Stem cell preparation for repairing skin ulcer |
| CN107080857A (en) * | 2017-03-29 | 2017-08-22 | 西南交通大学 | A kind of preparation method of the hemostatic material based on fibrin gel |
-
2018
- 2018-05-14 CN CN201810453594.XA patent/CN108635621A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101716382A (en) * | 2009-12-02 | 2010-06-02 | 浙江大学 | Preparation method of trinary composite stent of plasmid DNA / fibrin gel / polymer |
| WO2012103100A1 (en) * | 2011-01-24 | 2012-08-02 | Progenicare, Llc | Compositions and methods for promoting tissue regeneration |
| CN103041453A (en) * | 2013-01-18 | 2013-04-17 | 新乡医学院 | Double-layer skin covering material compositely built by collagen/fibrin glue-VEGF (vascular endothelial growth factor) and mesenchymal stem cell as well as preparation method and application of double-layer skin covering material |
| CN105708860A (en) * | 2016-01-26 | 2016-06-29 | 深圳爱生再生医学科技有限公司 | Stem cell preparation for repairing skin ulcer |
| CN107080857A (en) * | 2017-03-29 | 2017-08-22 | 西南交通大学 | A kind of preparation method of the hemostatic material based on fibrin gel |
Non-Patent Citations (1)
| Title |
|---|
| 陈克明等: "《骨髓间充质干细胞复合纤维蛋白凝胶修复大面积关节软骨缺损》", 《中国矫形外科杂志》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112263713A (en) * | 2020-09-21 | 2021-01-26 | 苏州大学附属第一医院 | Fibrin hydrogel scaffold loaded with human umbilical cord mesenchymal stem cells and its application |
| CN115463083A (en) * | 2022-08-03 | 2022-12-13 | 湖南师范大学 | Injectable hydrogel material and preparation and application methods thereof |
| CN119454917A (en) * | 2025-01-14 | 2025-02-18 | 温州医科大学 | Preparation method and application of cell lysate gel for treating oral ulcer |
| CN119454917B (en) * | 2025-01-14 | 2025-04-15 | 温州医科大学 | Preparation method and application of cell lysate gel for treating oral ulcer |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Yao et al. | Injectable Dual‐Dynamic‐Bond Cross‐Linked Hydrogel for Highly Efficient Infected Diabetic Wound Healing | |
| Peng | Hemostatic agents for prehospital hemorrhage control: a narrative review | |
| US9011929B2 (en) | Composition for inducing tissue regeneration by activating platelet-rich plasma (PRP) | |
| Li et al. | Fibrin gel as an injectable biodegradable scaffold and cell carrier for tissue engineering | |
| Wang et al. | A comparative study of the effects of concentrated growth factors in two different forms on osteogenesis in vitro | |
| Man et al. | The use of autologous platelet-rich plasma (platelet gel) and autologous platelet-poor plasma (fibrin glue) in cosmetic surgery | |
| De la Puente et al. | Cell culture in autologous fibrin scaffolds for applications in tissue engineering | |
| Wang et al. | Controlled dual delivery of low doses of BMP-2 and VEGF in a silk fibroin–nanohydroxyapatite scaffold for vascularized bone regeneration | |
| Adler et al. | Enhancing wound healing with growth factors | |
| US20100028311A1 (en) | Using of scaffold comprising fibrin for delivery of stem cells | |
| Kober et al. | Generation of a fibrin based three‐layered skin substitute | |
| Valbonesi | Fibrin glues of human origin | |
| Rioja et al. | Distributed vasculogenesis from modular agarose-hydroxyapatite-fibrinogen microbeads | |
| JP2015134815A (en) | Wound healing composition | |
| CN106913900B (en) | Silk fibroin hemostatic material and preparation method thereof | |
| CN108635621A (en) | Preparation method for the load stem cell fibrin gel for promoting wound healing | |
| Laschke et al. | The simpler, the better: tissue vascularization using the body’s own resources | |
| Zhang et al. | A novel collagen/platelet-rich plasma (COL/PRP) scaffold: preparation and growth factor release analysis | |
| CN115590811B (en) | A hydrogel preparation loaded with stem cells and its application | |
| CN107080857A (en) | A kind of preparation method of the hemostatic material based on fibrin gel | |
| Hong et al. | NIR‐Responsive Multifunctional Artificial Skin for Regenerative Wound Healing | |
| Stechison | Rapid polymerizing fibrin glue from autologous or single-donor blood: preparation and indications | |
| Khan et al. | Bioactive scaffolds in stem cell-based therapies for myocardial infarction: a systematic review and meta-analysis of preclinical trials | |
| US20190388516A1 (en) | Hemostatic products | |
| Zhao et al. | Temperature-activated PRP–cryogel for long-term osteogenesis of adipose-derived stem cells to promote bone repair |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20181012 |
|
| RJ01 | Rejection of invention patent application after publication |